Capricor Therapeutics, Inc.
Financials
Valuation Metrics
Capricor Therapeutics, Inc.'s Market Cap is $525M. At end of 2025 it was $1.41B. Ranked #2763 of 3,121 in US market (top 89%), #1201 of 1,463 on NASDAQ (top 82%), #221 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 83%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $525M | US#2,763/3,121 Sec#221/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-129M | US—/3,121 Sec—/266 |
| Total Assets | $369M | US#2,869/3,121 Sec#196/266 |
| Net Assets | $246M | US#2,606/3,121 Sec#173/266 |
| Employees | 231 | US#2,471/3,121 Sec#125/266 |
| Value | ||
| P/B | 2.13x | US#1,379/3,121 Sec#61/266 |
| EV/EBITDA | 0.51x | US#2/3,121 Sec#1/266 |
| FCF Yield | -24.73% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -52.56% | US#2,694/3,121 Sec#160/266 |
| ROA | -35.10% | US#2,920/3,121 Sec#173/266 |
| Revenue Growth | -100.00% | US#2,775/3,121 Sec#187/266 |
| Financial Health | ||
| Debt Ratio | 49.76% | US#564/3,121 Sec#141/266 |
| Total Debt | $91M | US#2,470/3,121 Sec#126/266 |
| FCF | $-130M | US#2,689/3,121 Sec#163/266 |
| Cash | $21M | US#2,857/3,121 Sec#256/266 |
| Current Ratio | 7.35x | US#342/3,121 Sec#107/266 |
| Net Debt/EBITDA | 0.06x | US#607/3,121 Sec#33/266 |
| Performance | ||
| 1Y Return | 41.56% | US#515/3,121 Sec#101/266 |
| 1M Return | 13.53% | US#33/3,121 Sec#9/266 |
| From 52W High | -77.56% | US#3,056/3,121 Sec#253/266 |
| 1Y MDD | -89.11% | US#3,108/3,121 Sec#261/266 |
| Trading | ||
| Volume | 2,857,704 shares | US#440/3,121 Sec#38/266 |
| Trading Value | $26M | US#1,492/3,121 Sec#116/266 |
| Per Share | ||
| EPS | $-2.23 | US—/3,121 Sec—/266 |
| BPS | $4.25 | US#2,340/3,121 Sec#136/266 |
Company Info
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.